Re­gen­eron’s gold­en goose Eylea may stave off biosim­i­lar com­pe­ti­tion un­til 2024 or be­yond

Al­most 10 years have passed since its first FDA ap­proval and Re­gen­eron’s mac­u­lar de­gen­er­a­tion in­jec­tion Eylea con­tin­ues to pile up sales to the tune of about $5 bil­lion per year, or more than half of Re­gen­eron’s an­nu­al rev­enues.

Those bil­lions are not ex­pect­ed to go any­where any­time soon thanks to com­pe­ti­tion, even as No­var­tis sub­sidiary San­doz an­nounced Mon­day that it’s be­gin­ning a Phase III tri­al for an Eylea biosim­i­lar in 460 pa­tients across 20 coun­tries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER